Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes

Conditions:   Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia Intervention:   Diagnostic Test: Flow cytometry analysis of neutrophil myeloperoxidase expression Sponsor:   University Hospital, Grenoble Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

We report the results of a prospective trial of lirilumab in patients with myelodysplastic syndrome(MDS). A total of 10 patients included. Higher-risk patients received lirilumab plus azacitidine, lower-risk received single agent lirilumab. Two patients achieved CR and 5 achieved marrow CR. Although the small sample size precludes definitive conclusions, the results of this study indicate the efficacy and safety of lirilumab in MDS.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
AbstractRecently, an immunodeficiency syndrome caused by guanine-adenine-thymine-adenine 2 (GATA2) deficiency has been described. The syndrome is characterized by (i) typical onset in early adulthood, (ii) profound peripheral blood cytopenias of monocytes, B lymphocytes, and NK cells, (iii) distinct susceptibility to disseminated non-tuberculous mycobacterial (NTM) and other opportunistic infections (particularly human papillomavirus), and (iv) a high risk of developing hematologic malignancies (myelodysplastic syndromes (MDS); acute myeloid leukemias (AML)). Considerable clinical heterogeneity exists among patients withGA...
Source: Annals of Hematology - Category: Hematology Source Type: research
Myelodysplastic syndromes (MDS) are a series of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and a propensity to transform to acute myeloid leukemia (AML) [1]. AML is a myeloid malignancy characterized by increased self-renewal, limited differentiation and deregulated proliferation of myeloid blasts. They may cause bone marrow failure and death within months or even weeks if diagnosis and treatment time is delayed. Recent studies showed that demethylating agents 5-azacytidine (AZA) and 5-aza-2-deoxycytidine (decitabine, DAC) may bring substantial survival...
Source: Leukemia Research - Category: Hematology Authors: Source Type: research
ConclusionResults indicate that prophylaxis is the leading antifungal strategy in French hematology units, regardless of the disease condition, representing 76% of prescriptions for antifungal therapy.FundingAstellas Pharma France.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research
Various myeloid neoplasms, including the myelodysplastic syndromes (MDS), bear a certain risk of progression to secondary acute myeloid leukemia (sAML). The evolution from low-risk to high-risk MDS and finally to sAML suggests that leukemogenesis is a multistep process. However, even before an overt neoplasm, such as an MDS, develops, “prediagnostic” clonal conditions may be identified. With the advent of large-scale genomic screens, such conditions may be detected quite frequently and early in apparently healthy individuals. Recent data suggest that these conditions increase with age and are indeed associated ...
Source: Pathobiology - Category: Pathology Source Type: research
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological diseases of ineffective hematopoiesis with a risk for progression to acute myeloid leukemia (AML) [1,2]. More than 80% of individuals with MDS are 65 years old or older at the time of diagnosis [3]; the average age at diagnosis is 67 years old [4]. Anemia and fatigue are common in MDS, and are often managed through red blood cell transfusions. In addition, MDS can transform into AML requiring intensive chemotherapy and prolonged hospital stays of approximately 30 days [5], which can lead to severe toxicities and functional impairments [5 –8].
Source: Leukemia Research - Category: Hematology Authors: Source Type: research
Myelodysplastic syndromes (MDS) is a heterogeneous group of hematopoietic stem cell disorders that are characterized by cytopenia and dysplastic changes in peripheral blood (PB) and bone marrow (BM) and a propensity to transform into acute myeloid leukemia (AML) [1]. The diagnosis of MDS is based on cytomorphology and cytogenetics. Good cytomorphological experience is required for a correct diagnosis of MDS, particularly lower-risk MDS. The French-American-British (FAB) classification [2] was the standard.
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research
Abstract Hematological diseases can lead to ocular manifestations. Retinal manifestation occurs in patients with anemia, leukemia, lymphoma, myeloproliferative and myelodysplastic syndromes. It is not uncommon for the ocular findings to be the first manifestation of the systemic disease. In these patients the correct diagnosis can be difficult because as a rule the retinal involvement is unspecific. In cases of unexplained retinal changes with hemorrhage and cotton wool spots, an underlying hematological disease should be suspected and the appropriate diagnostics should be recommended. PMID: 29881877 [PubMed ...
Source: Der Ophthalmologe - Category: Opthalmology Authors: Tags: Ophthalmologe Source Type: research
This article reviews the diagnosis, clinical characteristics, and treatment modalities of SDS, and reports advances in the understanding of the molecular pathophysiology of SDS.
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Source Type: research
International Journal of Urology, EarlyView.
Source: International Journal of Urology - Category: Urology & Nephrology Authors: Source Type: research
More News: Hospitals | Leukemia | Myelodysplastic Syndrome